BioWorld - Wednesday, February 4, 2026

Regulatory
Regulatory RSS Feed RSS

FDA icons and doctor

FDA advisory panel says no to test for opioid use disorder

Oct. 27, 2022
By Mark McCarty
A U.S. FDA advisory panel saw a number of problems in the clinical trial for the Avertd test for opioid use disorder (OUD), including the fact that the study failed to enroll a sufficiently ethnically diverse body of subjects. Perhaps more damning was that the advisory panel was uncertain as to whether the 15 single nucleotide polymorphisms (SNPs) evaluated in the test were helpful in sorting out which patients were truly at high risk of OUD, leading to an 11-2 vote that the probable benefits of the test do not outweigh the risks.
Read More
FDA approved icons and medical professional
2022 Medtech Conference

Shuren floats voluntary alternative pathway for digital device premarket review

Oct. 27, 2022
By Mark McCarty
Innovative medical devices are the norm for reviewers at the U.S. FDA’s Center for Devices and Radiological Health (CDRH), but regulatory innovation is a tougher climb. In response, CDRH director Jeff Shuren said at this year’s Medtech Conference in Boston that the agency is eyeing a voluntary alternative pathway (VAP) for novel digital technologies, although this concept is unlikely to see the regulatory light of day other than as a pilot program at any point in the next year or two, given the need for statutory authorization.
Read More

Regulatory actions for Oct. 27, 2022

Oct. 27, 2022
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.
Read More

Regulatory actions for Oct. 27, 2022

Oct. 27, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascletis, Astrazeneca, Beigene, Cellevolve, Cour, Hugel, Ipsen, Janssen, Novaccess, Petros, Seres.
Read More

Adcom cautiously gives ‘HI-FPHI’ to what could be first-in-class anemia drug

Oct. 26, 2022
By Mari Serebrov
GSK plc may have pushed the door open Oct. 26 for the use of a new class of oral drugs to treat anemia in U.S. patients with chronic kidney disease who are dialysis dependent. The U.S. FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 13-3 that the benefits of GSK’s daprodustat outweighed the risks in that population. However, the committee didn’t push the door wide enough for patients not on dialysis, voting 5-11 on the question of whether the drug’s benefits outweighed its risk in the nondialysis population, even though that group conceivably could see a greater benefit. The test now is whether the FDA will follow the committee’s lead.
Read More

Regulatory actions for Oct. 26, 2022

Oct. 26, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Nervgen, Regenerx, Rznomics, Timber.
Read More